Pippias Maria, Kramer Anneke, Noordzij Marlies, Afentakis Nikolaos, Alonso de la Torre Ramón, Ambühl Patrice M, Aparicio Madre Manuel I, Arribas Monzón Felipe, Åsberg Anders, Bonthuis Marjolein, Bouzas Caamaño Encarnación, Bubic Ivan, Caskey Fergus J, Castro de la Nuez Pablo, Cernevskis Harijs, de Los Ángeles Garcia Bazaga Maria, des Grottes Jean-Marin, Fernández González Raquel, Ferrer-Alamar Manuel, Finne Patrik, Garneata Liliana, Golan Eliezer, Heaf James G, Hemmelder Marc H, Idrizi Alma, Ioannou Kyriakos, Jarraya Faical, Kantaria Nino, Kolesnyk Mykola, Kramar Reinhard, Lassalle Mathilde, Lezaic Visnja V, Lopot Frantisek, Macario Fernando, Magaz Ángela, Martín de Francisco Angel L, Martín Escobar Eduardo, Martínez Castelao Alberto, Metcalfe Wendy, Moreno Alia Inmaculada, Nordio Maurizio, Ots-Rosenberg Mai, Palsson Runolfur, Ratkovic Marina, Resic Halima, Rutkowski Boleslaw, Santiuste de Pablos Carmen, Seyahi Nurhan, Fernanda Slon Roblero María, Spustova Viera, Stas Koenraad J F, Stendahl María E, Stojceva-Taneva Olivera, Vazelov Evgueniy, Ziginskiene Edita, Massy Ziad, Jager Kitty J, Stel Vianda S
ERA-EDTA Registry, Department of Medical Informatics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Hellenic Renal Registry, Board of Registry, Coordination and Control of RRT, General Hospital of Athens 'G. Gennimatas', Athens, Greece.
Clin Kidney J. 2017 Apr;10(2):154-169. doi: 10.1093/ckj/sfw135. Epub 2017 Jan 16.
This article summarizes the European Renal Association - European Dialysis and Transplant Association Registry's 2014 annual report. It describes the epidemiology of renal replacement therapy (RRT) for end-stage renal disease (ESRD) in 2014 within 35 countries. In 2016, the ERA-EDTA Registry received data on patients who in 2014 where undergoing RRT for ESRD, from 51 national or regional renal registries. Thirty-two registries provided individual patient level data and 19 provided aggregated patient level data. The incidence, prevalence and survival probabilities of these patients were determined. In 2014, 70 953 individuals commenced RRT for ESRD, equating to an overall unadjusted incidence rate of 133 per million population (pmp). The incidence ranged by 10-fold; from 23 pmp in the Ukraine to 237 pmp in Portugal. Of the patients commencing RRT, almost two-thirds were men, over half were aged ≥65 years and a quarter had diabetes mellitus as their primary renal diagnosis. By day 91 of commencing RRT, 81% of patients were receiving haemodialysis. On 31 December 2014, 490 743 individuals were receiving RRT for ESRD, equating to an unadjusted prevalence of 924 pmp. This ranged throughout Europe by more than 10-fold, from 157 pmp in the Ukraine to 1794 pmp in Portugal. In 2014, 19 406 kidney transplantations were performed, equating to an overall unadjusted transplant rate of 36 pmp. Again this varied considerably throughout Europe. For patients commencing RRT during 2005-09, the 5-year-adjusted patient survival probabilities on all RRT modalities was 63.3% (95% confidence interval 63.0-63.6). The expected remaining lifetime of a 20- to 24-year-old patient with ESRD receiving dialysis or living with a kidney transplant was 21.9 and 44.0 years, respectively. This was substantially lower than the 61.8 years of expected remaining lifetime of a 20-year-old patient without ESRD.
本文总结了欧洲肾脏协会-欧洲透析与移植协会注册中心的2014年年报。它描述了2014年35个国家终末期肾病(ESRD)的肾脏替代治疗(RRT)的流行病学情况。2016年,欧洲肾脏协会-欧洲透析与移植协会注册中心从51个国家或地区的肾脏注册机构收到了2014年正在接受ESRD的RRT治疗患者的数据。32个注册机构提供了个体患者层面的数据,19个提供了汇总患者层面的数据。确定了这些患者的发病率、患病率和生存概率。2014年,70953人开始接受ESRD的RRT治疗,相当于总体未调整发病率为每百万人口133例(pmp)。发病率相差10倍;从乌克兰的每百万人口23例到葡萄牙的每百万人口237例。在开始接受RRT治疗的患者中,近三分之二是男性,超过一半年龄≥65岁,四分之一的主要肾脏诊断为糖尿病。开始RRT治疗91天时,81%的患者接受血液透析。2014年12月31日,490743人正在接受ESRD的RRT治疗,相当于未调整患病率为每百万人口924例。这在欧洲各地相差超过10倍,从乌克兰的每百万人口157例到葡萄牙的每百万人口1794例。2014年进行了19406例肾移植,相当于总体未调整移植率为每百万人口36例。同样,这在欧洲各地差异很大。对于2005-2009年开始接受RRT治疗的患者,所有RRT模式下5年调整后的患者生存概率为63.3%(95%置信区间63.0-63.6)。一名20至24岁接受透析或肾移植的ESRD患者的预期剩余寿命分别为21.9年和44.0年。这大大低于一名20岁无ESRD患者的预期剩余寿命61.8年。